Nkarta said it expects initial data from a clinical trial testing its cell therapy candidate NKX019 in adults with ANCA-associated vasculitis (AAV) and other autoimmune diseases to be presented later this year. The Phase 1/2 Ntrust-2 trial (NCT06733935) is testing several doses of NKX019 in up to…